The startup develops radioactive bandages specifically designed for the treatment of non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma. This technology enables medical professionals to deliver targeted radiation therapy directly to tumors, improving treatment efficacy and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Non-melanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma, affect millions of people each year, often requiring radiation therapy. Traditional radiation treatments can be inconvenient and may necessitate sophisticated instrumentation in a clinical setting.
Solution
DB Therapeutics is developing a holmium-166-based radiotherapeutic bandage for treating skin cancer. The bandage is applied directly to the skin, delivering targeted radiation therapy to the tumor site without the need for complex equipment. This approach offers a potentially more convenient method for delivering radiation, improving patient access to treatment. The bandage is designed for external application, providing a localized radiation dose to the affected area.
Target Audience
The primary target audience includes medical professionals treating non-melanoma skin cancers, such as dermatologists and oncologists.
Features
- Holmium-166 based radiotherapeutic material.
- Bandage form factor for direct application to the skin.
- Designed for targeted radiation delivery to non-melanoma skin cancers.
- Aims to eliminate the need for sophisticated instrumentation in the clinic.